Lixte Biotechnology Holdings Inc Market Cap ($206.80)
Market Cap & Net Worth: Lixte Biotechnology Holdings Inc (LIXTW)
Lixte Biotechnology Holdings Inc market cap. Lixte Biotechnology Holdings Inc (NASDAQ:LIXTW) has a market capitalization of $206.80 ($206.80) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32053 globally and #6474 in its home market, demonstrating a -68.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lixte Biotechnology Holdings Inc's stock price $0.02 by its total outstanding shares 9400 (9.40K). Also see Lixte Biotechnology Holdings Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Lixte Biotechnology Holdings Inc Market Cap History (2020–2025)
Lixte Biotechnology Holdings Inc market cap history from 2020 to 2025. Data shows change from $8.46K to $206.80 (-51.19% CAGR). Check Lixte Biotechnology Holdings Inc (LIXTW) share price today for real-time trading data and today's change.
Lixte Biotechnology Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lixte Biotechnology Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Lixte Biotechnology Holdings Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LIXTW by Market Capitalization
Companies near Lixte Biotechnology Holdings Inc in the global market cap rankings as of November 4, 2026. Also see LIXTW total asset value for a full breakdown of the balance sheet.
Key companies related to Lixte Biotechnology Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Lixte Biotechnology Holdings Inc (2020–2025)
Market capitalization of Lixte Biotechnology Holdings Inc from 2020 to today. Between 2020 and today, Lixte Biotechnology Holdings Inc's market cap moved from $8.46K to $ 206.80, with a yearly change of -51.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $206.80 | -24.14% |
| 2024 | $272.60 | -23.68% |
| 2023 | $357.20 | -35.59% |
| 2022 | $554.60 | -86.59% |
| 2021 | $4.14K | -51.10% |
| 2020 | $8.46K | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Lixte Biotechnology Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $206.80 USD |
| MoneyControl | $206.80 USD |
| MarketWatch | $206.80 USD |
| marketcap.company | $206.80 USD |
| Reuters | $206.80 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more